Prospective Study of the sensiTVT

Sponsor
Medical University of Graz (Other)
Overall Status
Recruiting
CT.gov ID
NCT03603535
Collaborator
Medical University Innsbruck (Other)
197
1
74.8
2.6

Study Details

Study Description

Brief Summary

sensiTVT is a relatively new tape. The aim of this study is to analyze the objective and subjective outcome at one year follow-up.

Condition or Disease Intervention/Treatment Phase
  • Device: sensiTVT

Detailed Description

Stress urinary incontinence (SUI) is defined as the involuntary leakage during physical activity and situations that result in an increase of abdominal pressure like sneezing, coughing or laughing and affects up to 25% of women. Currently there are a number of tapes on the market with GYNECARE TVT EXACT® (Tension free Vaginal Tape) and TVT- Obturator being one of the tapes with the highest subjective and objective cure rates and relatively low adverse events in women with normal sphincter pressure. Due to the recent FDA announcements several tapes have been withdrawn from the market and several new ones have been designed. Data from other tapes are available, however data especially from newer tapes is lacking.

Study Design

Study Type:
Observational
Anticipated Enrollment :
197 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Study of the sensiTVT (Midurethral Sling) for the Surgical Treatment of Stress Urinary Incontinence
Actual Study Start Date :
Oct 8, 2018
Anticipated Primary Completion Date :
Sep 2, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. objective success of stress urinary incontinence [one year]

    determined by a standardized cough stress test at 300 ml bladder, a negative cough stress test is a success.

Secondary Outcome Measures

  1. Subjective success as determined using the Patient Global Impression of Improvement questionnaire. [3 months+ one year]

    defined as very much improved/much improved (1,2) on the Patient Global Impression of Improvement scale, while any other response (improved, same, worse, or much worse- 3-7) will be considered as failures. The Patient Global Impression of Improvement is a seven item scale validated for incontinence.

  2. Peri- and postoperative complications [3 months+ one year]

    any surgical complications recorded

  3. Subjective incontinence cure rate using the Incontinence Outcome Questionnaire [3 months+ one year]

    The Incontinence Outcome Questionnaire was validated for postoperative assessment of quality of life after surgical treatment for stress urinary incontinence and has 27 items with lower scores indicating worse treatment outcome. The total score is calculated.

  4. quality of life using the Kings Health Questionnaire [3 months+ one year]

    The Kings Health Questionnaire was validated in women with stress urinary incontinence and assesses the impact of incontinence on quality of life. The eight subscales ("domains") scored between 0 (best) and 100 (worst). The Symptom Severity scale is scored from 0 (best) to 30 (worst); lower scores indicate better QoL. Success in terms of the study is defined as 10 points improvement on the total Kings Health Questionnaire score.

  5. Subjective bother using the Patient Global Impression of Severity [3 months+ one year]

    Patient Global Impression of Severity The Patient Global Impression of Severity is a 7-item urinary symptom severity scale that is used to rate the severity of a specific condition -a single-state scale. The higher the number the worse the outcome of subjective bother of stress urinary incontinence.

  6. Patient satisfaction measured using a visual analogue scale [3 months+ one year]

    Patient satisfaction is defined as a score 8 to 10 on a 10-point visual analogue scale

  7. Sexual health using the Pelvic Organ Prolapse Incontinence Sexual Questionnaire [3 months+ one year]

    The Pelvic Organ Prolapse Incontinence Sexual Questionnaire is a 20 item questionnaire and is the primary measure used to assess sexual function in women with urinary incontinence and prolapse. Mean subscale scores are calculated by summing the valid responses to items in the subscale and then divided by the number of items with valid responses. The higher the subscores, the worse the outcome.

  8. Erosion rate [3 months+ one year]

    Erosion rate from the tape in the vagina or bladder

  9. Reoperation rate [3 months+ one year]

    Reoperation rate

  10. De novo urgency [3 months+ one year]

    De novo OAB- overactive bladder as determined by clinical history taking

  11. De novo pain in the operated region [3 months+ one year]

    De novo pain in the operated region as determined by clinical history taking

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes

Inclusion criteria

  • Planned surgery for verified predominant stress urinary incontinence

  • women between 18 and 80 years of age

  • good German language skills

  • informed consent

Exclusion criteria:
  • Pregnant or lactating women

  • Active surgical treatment for invasive malignant diseases within 3 months

  • Contraindications for surgery or anesthesia

  • Severe neurologic disease

  • Concomitant prolapse surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Obstetrics, Medical University Graz Graz Austria 8045

Sponsors and Collaborators

  • Medical University of Graz
  • Medical University Innsbruck

Investigators

  • Principal Investigator: Daniela Gold (prev. Ulrich), MD PhD, Universitätsklinik für Frauenheilkunde und Geburtshilfe

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medical University of Graz
ClinicalTrials.gov Identifier:
NCT03603535
Other Study ID Numbers:
  • 29-481 ex 16/17
First Posted:
Jul 27, 2018
Last Update Posted:
Mar 15, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Medical University of Graz
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2022